SB 204741
SIGMA/S0693 - >98% (HPLC)
Synonym: N-
CAS Number: 152239-46-8
Empirical Formula (Hill Notation): C14H14N4OS
Molecular Weight: 286.35
MDL Number: MFCD00923644
Linear Formula: C14H14N4OS
Product Type: Chemical
| assay | >98% (HPLC) |
| color | off-white to tan |
| form | solid |
| InChI | 1S/C14H14N4OS/c1-9-7-13(2 |
| InChI key | USFUFHFQWXDVMH-UHFFFAOYSA |
| originator | GlaxoSmithKline |
| Quality Level | 100  |
| SMILES string | Cc1cc(NC(=O)Nc2ccc3n(C)cc |
| solubility | DMSO: soluble >20 mg/mL |
| storage temp. | 2-8°C |
| Application: | SB 204741 has been used as a 5-hydroxytryptamine receptor 2B (Htr2B) antagonist: • to inhibit Htr2b signaling to test its effect on hepatic stellate cell (HSC) activation in three-month-old adult zebrafish • to test its effect on the inhibition of fluoxetine effects in depressive-like behavioral studies in mice • to test its effect in reducing scratching behavior evoked by sertraline in mice |
| Biochem/physiol Actions: | 5-HT2B serotonin receptor antagonist. |
| Biochem/physiol Actions: | SB 204741 reduces the synaptic facilitation induced by the low dose of buprenorphine in spinal C-fiber synapses. |
| Features and Benefits: | This compound was developed by GlaxoSmithKline . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Legal Information: | Sold for research purposes under agreement from GlaxoSmithKline |
| Packaging: | 10, 50 mg in glass bottle |
| Symbol |  GHS07 |
| Signal word | Warning |
| Hazard statements | H315 - H319 - H335 |
| Precautionary statements | P302 + P352 - P305 + P351 + P338 |
| Hazard Codes | Xi |
| Risk Statements | 36/37/38 |
| Safety Statements | 26-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | >98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |